CEFTIN

Compare CEFTIN  to:
Compare
Compare

Generic Name for CEFTIN

Cefuroxime (as axetil) 250mg, 500mg; tabs.

Legal Classification:

Rx

Pharmacological Class for CEFTIN

Cephalosporin.

Manufacturer of CEFTIN

GlaxoSmithKline Pharmaceuticals

Indications for CEFTIN

Susceptible mild to moderate infections including pharyngitis/tonsillitis, acute maxillary sinusitis, bronchitis, acute otitis media; uncomplicated skin and skin structure, UTIs, gonorrhea; early Lyme disease.

Adult dose for CEFTIN

≥13 years: Pharyngitis/tonsillitis, sinusitis: 250mg twice daily for 10 days. Acute bacterial exacerbations of chronic bronchitis, skin and skin structure infections: 250–500mg twice daily for 10 days. Secondary bacterial infections of acute bronchitis: 250–500mg twice daily for 5–10 days. UTIs: 250mg twice daily for 7–10 days. Gonorrhea: 1g as a single dose. Lyme disease: 500mg twice daily for 20 days.

Children's dosing for CEFTIN

Swallow tab whole, or use susp. Otitis media, sinusitis: 250mg twice daily for 10 days.

Also:

Warnings/Precautions for CEFTIN

Tabs and susp not bioequivalent; do not interchange on a mg/mg basis. Penicillin or other allergy. History of colitis; discontinue if colitis occurs and treat. Renal impairment. Monitor prothrombin time in renal or hepatic dysfunction, stabilized on anticoagulant, poor nutritional state, or long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: consider discontinuing nursing during treatment.

Interactions for CEFTIN

May cause false (+) Fehling's or Benedict's soln, Clinitest, or Coomb's test. Antacids, others that decrease gastric acidity may inhibit absorption. Potentiated by probenecid. Caution with potent diuretics, other nephrotoxic drugs.

Adverse Reactions for CEFTIN

GI disturbances, transient increase of AST, ALT, LDH, eosinophilia, bitter taste; convulsions (overdose).

How is CEFTIN supplied?

Tabs—20, 60
Susp 125mg/5mL—100mL
Susp 250mg/5mL—50mL, 100mL

Related Disease:

Infections, bacterial~systemic antiinfectives
Sinusitis

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions